Renal cancer is the disease in which certain tissues of the kidney starts to grow uncontrollably and form a tumor.

It is also called as renal adenocarcinoma or hypernephroma.

Classic triad of symptoms are flank pain, palpable abdominal mass and gross hematuria.

Renal Cancer References

  1. Albiges L, Gizzi M, Carton E, et al. Axitinib in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2015 May;15(5):499-507. doi: 10.1586/14737140.2015.1033408. PMID: 25907705
  2. American Cancer Society. Kidney cancer (adult) – renal cell carcinoma overview. ACS. . Jan 2015. Accessed 5 Oct 2015.
  3. American Society of Clinical Oncology. Cabozantinib improves upon the standard of care for advanced kidney cancer. ASCO. Jan 2016.
  4. American Urological Association. Follow-up care for renal cancer. AUA. Apr 2013.
  5. Atkins M. Clinical manifestations, evaluation, and staging of renal cell carcinoma. UpToDate. Sep 2015.
  6. Atkins M, Choueiri T. Epidemiology, pathology, and pathogenesis of renal cell carcinoma. UpToDate. Mar 2015. Accessed 5 Oct 2015.
  7. Atkins M. Overview of the treatment of renal cell carcinoma. UpToDate. Jul 2015. Accessed 5 Oct 2015.
  8. Bracarda S, Hutson TE, Porta C, et al. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer. 2012 Apr;106(9):1475-1480. doi: 10.1038/bjc.2012.89. PMID: 22441644
  9. Cancer Therapy Advisor. Renal cell carcinoma treatment regimens.,-kidney,-and-other-urologic-cancers/category/152/0/.
  10. Cancer Treatment Centers of America. Kidney cancer types.
  11. Canfield S, Dabestani S, Hofman F, et al. European Association of Urology. Guidelines on renal carcinoma. EAU. Mar 2015.
  12. Chemocare. Nivolumab.
  13. Cohen R. Pathology of clear cell carcinoma. eMedicine. Feb 2014. Accessed 5 Oct 2015.
  14. da Silva RD, Gustafson D, Nogeira L, et al. Targeted therapy for metastatic renal carcinoma: an update. Journal of Kidney Cancer and VHL. 2014;1(6):63-73. doi: 10.15586/jkcvhl.2014.14.
  15. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2014 Sep;25(Suppl 3):iii49–iii56. doi: 10.1093/annonc/mdu259. Accessed 5 Oct 2015. PMID: 25210086
  16. European Association of Urology. Guidelines on renal cell carcinoma (2015). EAU.
  17. Johnson M. Renal cancer: Symptoms, diagnosis, pathology & prognosis.
  18. Kidney Health Australia. Kidney cancer. Accessed 5 Oct 2015.
  19. Kidney Cancer Canada. Types of kidney cancer and related syndromes.
  20. Larkin J, Mayer F, Wood L, et al. Axitinib for the treatment of metastatic renal cell carcinoma: Recommendations for therapy management to optimize outcomes. Am J Clin Oncol. 2014 Aug;37(4):397-403. doi: 10.1097/COC.0b013e31827b45f9. Accessed 6 Jan 2016. PMID: 23357974
  21. Lawrence L. METEOR: Cabozantinib improves survival in advanced kidney cancer. Sep 2015. Accessed 13 Jan 2016.
  22. Lee CH, Hotker A, Voss M, et al. Bevacizumab monotherapy as salvage therapy for advanced clear cell renal cell carcinoma pretreated with targeted drugs. Clin Genitourin Cancer. 2016 Feb;14(1):56-62. doi: 10.1016/j.clgc.2015.07.010. PMID: 26404107
  23. Madell R. 5 Types of renal carcinoma: What you need to know. Healthline. Feb 2014. Accessed 5 Oct 2015.
  24. Motzer R, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2015: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Feb;13(2):151-159. PMID: 25691606
  25. Motzer RJ, Alyasova A, Karpenko A, et al. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) [Abstract]. Ann Oncol. 2016 Mar;27(3):441-448 . doi: 10.1093/annonc/mdv612. PMID: 26681676
  26. Muglia V, Adison P. Renal cell carcinoma: Histological classification and correlation with imaging findings. Radiol Bras. 2015 May-Jun;48(3):166-174. doi: 10.1590/0100-3984.2013.1927. Accessed 5 Oct 2015
  27. National Cancer Institute. General information about renal cancer. NIH. Jul 2015.
  28. National Cancer Institute. Nivolumab. NIH.
  29. National Cancer Institute. Kidney cancer – for health professionals. NIC.
  30. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 2.2014. NCCN. Dec 2013.
  31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 2.2016. NCCN. Nov 2015.
  32. North S, Basappa N, Canil C, et al. Management of advance kidney cancer: Canadian kidney cancer forum consensus update. CUAJ. 2015 May-Jun;9(5-6):164-170.
  33. Reaume MN, Graham G, Tomiak E, eta al. Canadian guideline on genetic screening for hereditary renal cancers. CUAJ. 2013 Sep-Oct;7(9-10):319-323.
  34. Rendon R, Kapoor A, Breau R, et al. Surgical management of renal cell carcinoma: Canadian kidney cancer forum consensus. CUAJ. 2014 May-Jun;8(5-6):E398-E412. Accessed 5 Oct 2015
  35. Results from Phase 2 Trial Investigating Lenvatinib in Metastatic Renal Cell Carcinoma Published in The Lancet Oncology.
  36. Sachdeva K. Renal cell carcinoma clinical presentation: history, physical examination, staging. eMedicine. Sep 2015. Accessed 5 Oct 2015.
  37. Sachdeva K. Renal cell carcinoma workup. eMedicine. Dec 2015.
  38. Schmidinger M, Larkin J, Porta C. Evidence and experience for the management of metastatic renal cell carcinoma. EJC Supplements. 2013:001-8. doi: 10.1016/j.ejcsup.2013.07.001.
  39. Society of Interventional Radiology. Interventional radiology treatments for kidney cancer. SIR. 2015. Accessed 5 Oct 2015.
  40. Stephenson R. Guidelines for the management of urological cancer. Kidney cancer treatment guidelines. Aug 2012.
  41. Urology at UCLA. Kidney cancer symptoms, treatment and diagnosis. UCLA.
  42. Weil Cornell Medical College, James Buchanan Brady Foundation, Department of Urology. Kidney cancer/general information. Accessed 5 Oct 2015.
  43. White V. Eisai submits MAA for Lenvatinib in renal cell carcinoma. europeanpharmaceuticalreview. Jan 2016. Accessed 13 Jan 2016.
  44. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 May;30(5):706-720. doi:10.1093/annonc/mdz056. PMID: 30788497
  45. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 2.2020. NCCN. 5 Aug 2019.
Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 3 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.